![](/img/cover-not-exists.png)
Rationale and design of the Anti-Xa Therapy to Lower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome–Thrombolysis in Myocardial Infarction 51 (ATLAS-ACS 2 TIMI 51) trial: A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome
C. Michael Gibson, Jessica L. Mega, Paul Burton, Shinya Goto, Freek Verheugt, Christoph Bode, Alexei Plotnikov, Xiang Sun, Nancy Cook-Bruns, Eugene BraunwaldVolume:
161
Year:
2011
Language:
english
Pages:
65535
DOI:
10.1016/j.ahj.2011.01.026
File:
PDF, 428 KB
english, 2011